Results 251 to 260 of about 3,468,016 (309)

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Fragment Autoantigens Stimulated T-Cell-Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine. [PDF]

Adv Sci (Weinh)
Li Y, Chen H, Shen Q, Liu Y, Li P, Ma Y, Wang Y, Li S, Yan X, Liu L, Shuai J, Wu M, Ouyang Q, Kong FS, Yang G.   +14 more
europepmc   +1 more source

Boosting mRNA cancer vaccine efficacy via targeting Irg1 on macrophages in lymph nodes. [PDF]

Theranostics
Wei W, Yang X, Chen Y, Che M, Ye Y, Deng Y, Su M, Sun Y, Meng J, Hu Y, Wang J, Wang Y, Feng Z, Zhou Z, Li Y, Li Q, Zhang Z, Wu B, Zhang H, Qin Y, Wen L, Wan C, Yang K.   +22 more
europepmc   +1 more source

Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review. [PDF]

Ther Adv Med Oncol
Gomez-Randulfe I, Lavender H, Symeonides S, Blackhall F.   +3 more
europepmc   +1 more source

Challenges and New Directions in Therapeutic Cancer Vaccine Development. [PDF]

Vaccines (Basel)
Pan D, Liu J, Huang X, Wang S, Kuerban K, Yan Y, Zhu YZ, Ye L.   +7 more
europepmc   +1 more source

Developing cancer vaccine with carcinoembryonic antigen and IGF-1R as immunostimulants using immunoinformatics approach. [PDF]

Korean J Clin Oncol
Ezediuno LO, Ockiya MA, Awoniyi LO, Sangodare AO, David KB, Robert FO.   +5 more
europepmc   +1 more source

FcRn-guided antigen trafficking enhances cancer vaccine efficacy. [PDF]

Cancer Immunol Immunother
Hong M, Liu M, Zhu F, Zhao D, Liu G, Han T, Fei C, Zeng W, Chen S, Wu Q, Li B, Wu S, Shang Y, Ma H, Zhou S, Xu S, Jin T.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cancer vaccines

Molecular Medicine Today, 1997
A better understanding of immune recognition of cells has led to identification of potential new targets on tumor cells. Noticeable successes in melanoma have been immunization with the GM2 ganglioside vaccine, and the identification of novel antigens such as MAGE, BAGE and GAGE recognized by T cells cloned from cancer patients with regressing disease.
T F, Greten, E M, Jaffee
  +8 more sources

Cancer vaccines

Seminars in Oncology Nursing, 2003
To provide a review of cancer vaccines, how they work, and the current state of the science underlying these treatments.Research studies, review articles, book chapters, personal communications.Vaccines have been studied in a variety of malignancies; however, melanoma has provided the best tumor model for vaccination.
Paula M, Muehlbauer, Douglas J, Schwartzentruber   +1 more
openaire   +4 more sources

CANCER VACCINES

Hematology/Oncology Clinics of North America, 2001
Attempts to generate an anticancer immune response in vivo in patients with cancer have taken several forms. Although to date there have been relatively few published studies describing the effects of the approach in hematologic malignancy, that circumstance is expected to change rapidly during the next few years. In solid tumors, it is not known which,
R F, Rousseau, C, Hirschmann-Jax, S, Takahashi, M K, Brenner   +3 more
openaire   +4 more sources